Clinical trial · Observational
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC. Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer, Small Cell | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HYCAMTIN | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- HYCAMTIN
- interventionNames
- Drug: HYCAMTIN
Primary outcomes (1)
- measure
- Registry with disease, treatment and outcome data collected.
- timeFrame
- 6-9mth recruitment period, 18mth study duration.
Secondary outcomes (1)
- measure
- survival rates
- timeFrame
- 18 month period
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or Female \>/= 18 years * Diagnosis of small cell lung cancer * Patient newly diagnosed with SCLC * Has given written informed consent (if applicable) Exclusion Criteria: * Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix. * Patient presenting with recurrence of SCLC. * Patients who has received any chemotherapy for the SCLC.
References
Publications (0)
Data not yet available